Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Contributed by: Business Wire

Logo

Tags

Technology

Neurology

Genetics

Clinical Trials

Other Health

Biotechnology

General Health

Pharmaceutical

Health

Artificial Intelligence

Ferrer

More Like This

PR Newswire associated0

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients

AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations

AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility